Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rineterkib SCHEMBL29456943 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL20145842 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL19813110 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL19812954 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL16680430 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL19813109 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL16679667 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL21244152 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL21244156 | 1.00 | MAPK1 (1.00) | MAPK1 | |
| Rineterkib SCHEMBL16680095 | 1.00 | MAPK1 (1.00) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230090389-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | claimed |
| US-20210121460-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, TRAMETINIB AND AN ERK INHIBITOR | NOVARTIS AG (CH) | 2021-04-29 | — | — | US | claimed |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | NOVARTIS AG (CH) | 2020-05-26 | — | — | US | claimed |
| CN-111163781-A | Combination of an MDM2 inhibitor and an ERK inhibitor for the treatment of cancer | 诺华股份有限公司 | 2020-05-15 | — | — | CN | claimed |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoirens Serviece (FR) | 2024-06-06 | — | — | US | disclosed |
| EP-4288434-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | Les Laboratoires Servier (FR) | 2023-12-13 | — | — | EP | disclosed |
| US-20230090389-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| CN-111163781-A | Combination of an MDM2 inhibitor and an ERK inhibitor for the treatment of cancer | 诺华股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090389-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, AN ERK INHIBITOR AND A SHP2 INHIBITOR | DUSP2, PTPN1, PTPN6 | MAPK1 29/4885 |
| US-10660888-B2 | Aminoheteroaryl benzamides as kinase inhibitors | ABL1, MAP3K12, MAP3K2 | MAPK1 95/4885 |
| US-20240182464-A1 | SELECTIVE BCL-XL PROTAC COMPOUNDS AND METHODS OF USE | CRBN, XIAP, BCL2L11 | MAPK1 1748/4885 |
| US-20210121460-A1 | A TRIPLE PHARMACEUTICAL COMBINATION COMPRISING DABRAFENIB, TRAMETINIB AND AN ERK INHIBITOR | BRAF, MAPK3, MAPK1 | MAPK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.